Almac's new Asia Pacific packaging hub inspected by Singapore's HSA

By Gareth Macdonald contact

- Last updated on GMT

Almac in Singapore
Almac in Singapore

Related tags: Pharmaceutical industry, Pharmacology, Clinical trial

Singapore regulators have inspected a trial packaging site set up by Almac last month to support growing global demand for services in the region.

The facility – which is next to Changi airport – will provide clinical trial primary and secondary packaging services for trials being run across Asia Pacific, including those being run through the Norther Ireland-headquartered-contractor’s satellite office in Japan.

A spokesperson told us the investment in Singapore was a reflection of both the increasing about of pharmaceutical activity on the island as well is the locations positions as a central hub – in so far as that is possible – in the Asian Pacific region.

Singapore has emerged as a regional hub for the pharma industry, which is expected to grow at a CAGR of 2% by 2020, as a result of its strong industrial base, effective IP protection laws, excellent innovation infrastructure and political stability and as a result, 23% of global clinical trials are currently conducted in Asia​.” 

We have therefore recognised that by using Singapore as a base for our operations, supported by a regional support centre based in Japan, we are better equipped to support our Asia-based clients in their own time zones and languages​.”

The Singapore facility will also work as part of Almac’s global supply network – which includes sites in the UK and the US – according to the spokesperson.

Establishing primary and secondary production of clinical trial material at our Singapore facility was key strategic decision to ensure that Almac was able to offer our full range of clinical packaging capabilities globally​.” 

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more